HealthEquity Inc. (HQY)
HealthEquity: Flywheel Keeps Spinning
HealthEquity, Inc. remains an asset-light growth opportunity, with a $120/share price target supported by strong Q2 FY26 results. HQY's recurring, asset-linked revenues, 70%+ gross margins, and expanding HSA penetration drive robust returns and positive operating leverage. Management's disciplined capital allocation, improving cost structure, and new legislative tailwinds expand HQY's total addressable market and growth runway.
Exploring Analyst Estimates for HealthEquity (HQY) Q3 Earnings, Beyond Revenue and EPS
Evaluate the expected performance of HealthEquity (HQY) for the quarter ended October 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Here's Why HealthEquity (HQY) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Reasons to Add HealthEquity Stock to Your Portfolio for Now
HQY rides on strong HSA growth, AI-driven efficiency gains and solid Q2 results, though data security threats remain a key risk.
HealthEquity Rolls Out Agentic AI to Elevate Member Support Experience
HQY's new agentic AI is likely to provide faster, more intuitive support across channels, aiming to boost member satisfaction.
Final Trades: Taiwan Semi, HealthEquity, CBOE Global Markets and the XBI
The Investment Committee give you their top stocks to watch for the second half.
Why HealthEquity (HQY) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
HQY Expands Access With GLP-1 Telehealth & Direct HSA Platforms
HealthEquity rolls out GLP-1 telehealth and direct HSA enrollment platforms, targeting affordability and growth amid rising healthcare costs and regulatory expansion.
Here's Why HealthEquity (HQY) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
HealthEquity: Swing Trading Stock With A Beat And Raise
HealthEquity reported strong Q2 results with revenue and earnings beats, but valuation remains stretched, justifying a neutral-to-cautiously bullish rating. The company operates in a large, growing healthcare savings market, with solid account and asset growth driven mostly by organic expansion. Financial metrics were robust: revenue up 8.6%, adjusted EBITDA up 18%, and margin expansion, with continued share repurchases but no dividend yet.
HealthEquity Stock Gains as Q2 Earnings Beat Estimates, Revenues Up Y/Y
HQY's Q2 results reflect EPS growth of 25.6% year over year, revenue growth of 8.6% and a 12% increase in HSA. The company also updates its fiscal 2026 guidance.
HealthEquity: Scale Platform With Asset‑Linked Revenues And Thick Incremental Margins
HQY remains a buy for long-term investors, with exceptional economics, high margins, and capital-light growth despite recent multiple contraction. Q1 FY26 results showed strong revenue and earnings growth, margin expansion, and operating leverage, confirming the business is scaling efficiently. The recurring, asset-linked revenue model benefits from secular healthcare tailwinds, high switching costs, and robust cash conversion cycles.
